Pharmaron Beijing Co Ltd

Pharmaron released its semi-annual report for 2026, achieving operating revenue of 7.595 billion yuan, up 17.92% year on year, and net profit attributable to shareholders of the listed company of 750 million yuan, up 6.96% year on year. During the reporting period, the company's newly signed orders grew by more than 30% year on year, with newly signed orders for CDMO services up more than 50% year on year. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert capital reserve into share capital.

WuXi AppTec released its 2026 half-year report, with first-half net profit attributable to the parent company surpassing 10 billion yuan for the first time to reach 11.08 billion yuan, up 29.43 percent year on year. The results triggered multiple limit-up moves in the CXO and pharmaceutical sectors across both A-shares and Hong Kong stocks on August 4. WuXi AppTec's A-shares hit the 10 percent daily limit up that day, while its Hong Kong shares closed 11.17 percent higher. The company's first-half revenue was 28.9 billion yuan, up 38.93 percent year on year, and it raised its full-year revenue guidance to a range of 58.5 billion to 60.5 billion yuan. Buoyed by WuXi AppTec's performance, A-share companies such as GemPharmatech, Porton Pharma Solutions, and Medicilon rose over 13 percent, while Hong Kong-listed GenScript Biotech gained over 11 percent, and Pharmaron, Asymchem, and Tigermed climbed more than 5 percent. Several CXO firms had previously issued positive profit alerts. Pharmaron expects first-half net profit to grow 34 to 45 percent year on year, Joinn Laboratories forecasts a staggering 884.9 to 1,377.4 percent surge in net profit attributable to the parent, and Medicilon anticipates swinging to a profit. The innovative drug segment also strengthened, with Biopuris and HitGen rising over 14 percent, while Luoxin Pharmaceuticals, Jimin Health, and ZBD Pharmaceutical hit the 10 percent daily limit up. Meanwhile, Alphamab announced it has granted overseas rights for its TROP2/HER3 bispecific antibody-drug conjugate SKN016 to Pathos AI, in a deal with a total potential value exceeding 2.2 billion US dollars.

Joinn Laboratories issued an earnings forecast, projecting that its net profit attributable to the parent company for the first half of 2026 will skyrocket by 884.9% to 1,377.4% year-on-year, mainly driven by fair value changes in biological assets due to rising prices of laboratory monkeys. The company expects operating revenue for the same period to be between 669 million and 739 million yuan, an increase of about 0% to 10.5% year-on-year, with fair value changes in biological assets contributing approximately 703 million to 777 million yuan to net profit. Boosted by this news, the CRO sector surged across the board today. Joinn Laboratories' A-shares hit the daily limit up, ChemPartner achieved a 20% daily limit up, and companies like Sunstone Development and Wanbang Pharmaceutical rose over 10%. In addition, Pharmaron also forecasted that its first-half net profit attributable to the parent company would grow by 4% to 10% year-on-year, with new orders increasing by over 30% year-on-year. Currently, there is a shortage of cynomolgus monkeys, and their price has exceeded 200,000 yuan.

The General Office of the National Medical Products Administration has released a draft proposal to include eligible cell and gene therapy drugs in a 30-day review and approval pathway for innovative drug clinical trial applications. Previously, the review cycle was 60 working days, effectively doubling approval efficiency. The policy aligns with the forthcoming regulations on clinical research and translational application of new biomedical technologies, as well as the announcement issued last September on optimizing the review and approval of innovative drug clinical trials. Together, they enhance the industry ecosystem across multiple dimensions, including review efficiency, compliance pathways, and innovation orientation. The draft encourages global simultaneous development and international multi-center clinical trials, and focuses on key areas such as malignant tumors and rare diseases to guide resource concentration. Several A-share listed companies with a presence in the cell and gene therapy sector are expected to benefit, including Obio Technology, Pharmaron, and Porton Pharma Solutions. The Wind Innovative Drug Index has rebounded by more than 20 percent since mid-June.

The pharmaceutical sector rallied strongly during trading on the 6th, with weight-loss drug and innovative drug concepts standing out. Shouyao Holdings and Gan & Lee Pharmaceuticals were among multiple stocks that hit their daily limit up. As of press time, Shouyao Holdings surged by the 20 percent daily limit, Hotgen Biotech rose about 14 percent, Mabwell Bioscience, InventisBio, and Shanghai Yizhong Pharmaceutical gained over 10 percent, Gan & Lee Pharmaceuticals, Huahai Pharmaceutical, and Menovo Pharmaceutical also hit their daily limit up, BeiGene and Pharmaron climbed over 7 percent, and Hengrui Medicine advanced more than 5 percent. In the Hong Kong market, Duality Biologics, InnoCare Pharma, and Sino Biopharmaceutical rose over 10 percent, while WuXi XDC and Pharmaron gained more than 5 percent. On the news front, the National Medical Products Administration is soliciting public comments on optimizing the review and approval of cell and gene therapy drugs, encouraging clinically value-oriented R&D innovation, focusing on key areas such as malignant tumors and rare diseases, and placing eligible drugs into a 30-day review and approval pathway. Meanwhile, the overseas expansion of innovative drugs is accelerating. Since 2026, the total value of China's innovative drug license-out deals has reached 94.3 billion US dollars, up 81 percent year-on-year, with upfront payments reaching 5.5 billion US dollars, up 124 percent year-on-year, reflecting growing overseas recognition of China's innovative drug pipeline. CICC noted that leading innovative drug companies are shifting from the R&D investment phase into a positive cycle of commercial scale-up and overseas licensing revenue realization.